Twitter Twitter Facebook Facebook Linked In Linked In Zone In Zone In Google Plus Zone In
 
eNews

Research Update

New Perspectives on Antisense Oligos

In 1978, Zamecnik and Stephenson first demonstrated the ability to target and modulate gene expression through short synthetic oligos. Since then, antisense oligonucleotide (ASO)-based therapeutics have been studied extensively. However, only a single ASO drug has obtained FDA approval since their initial discovery. As with many therapeutic strategies, target affinity, biostability, delivery and off-target effects have been central to the challenges facing ASO-based therapy in the clinic. To combat these obstacles, various aspects of the oligonucleotides have been altered, including the length of the oligonucleotide. Traditionally, the length of an ASO has been ~20-22 nucleotides, however recent evidence emphasizes the fact that shortening an ASO may be an effective targeting strategy in multiple contexts.

Read More
 

GMP Manufacturing
We’ve combined our extensive nucleic acid modification experience with a new state-of-the-art GMP manufacturing facility. Learn More

Featured New Products
Thieno modified NTPs & oligo modifications

Poster
Get a sneak peek of our IRT poster, Hot Start Activation of DNA LCR Using CleanAmp™!
 
Recent Blog Post

Could the Current Ebola Outbreak Have Been Prevented?

  • Deadliest Outbreak Yet Shows no Sign of Abating
  • Lack of Funds Hampered Clinical Development of Drugs and Vaccines
  • Treatments Exist so Why are Doctors Left with no Cure to Offer the Infected?

The fact that the Ebola virus was identified almost 40 years ago and there’s been ongoing research ever since begs the question, “Was the current Ebola outbreak preventable?”

Read More

Smartphone

A doctor in Sierra Leone enters the high-risk area of the Ebola treatment center. Credit: Sylvain Cherkaoui/Cosmos/eyevine (taken from Nature)
 

GMP TriLink has been a key supplier of high quality research grade and diagnostic grade GMP material since 1996, and now offers therapeutic GMP production. Our new, state-of-the-art 2,000 sq ft GMP manufacturing facility includes validated ISO Class 7 and ISO Class 8 clean rooms, specifically designed to facilitate fast turnaround of IND (Phase 0) and Phase 1 materials. TriLink's extensive experience in modified nucleic acid synthesis is now at your disposal to investigate the safety and efficacy of unusual constructs. Contact us to discuss your project today!
 
New! Isomorphic Fluorescent Nucleotides

We've expanded our collection of intrinsically fluorescent nucleotides with the addition of thienos. These unique molecules were designed by Dr. Yitzhak Tor of UCSD. Thieno nucleotides serve an unparalleled role in exploring fundamental biochemical transformations and facilitate the fabrication of biophysical and discovery assays. DrTor
  Prof. Yitzhak Tor, UCSD
View NTPs
View Oligo Modifications
Previous Blog Post

mtDNA Replacement: Eliminating Disease or Creating Designer Babies?
  • Mitochondrial DNA Replacement to Preclude Mitochondrial Disease Shown Feasible in Monkeys
  • US FDA Advisors Ponder Pros and Cons for Allowing Human Clinical Trials Amidst “Designer Baby” Concerns
  • UK Government Decision “Up in the Air”

Read More
View mitoPrimers™ for mtDNA Analysis

 

© 2014 TriLink BioTechnologies, Inc. | All Rights Reserved